Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

The collaboration has two components, development of allogeneic T-cell therapies for up to five shared targets and development of novel personalised allogeneic T-cell therapies. For each component, ADAP will be responsible for developing clinical candidates using its iPSC-derived platform to produce T-cells. Genentech will be responsible for the input of TCRs and subsequent clinical development and commercialisation.

ADAP will receive $150M upfront, the same amount over the next five years in additional payments, and development, regulatory and commercial milestones payments potentially exceeding $3B, as well as royalties (mid-single to low-double digits), across multiple programs.

https://www.globenewswire.com/news-release/2021/09/07/2292303/35803/en/Adaptimmune-Enters-into-a-Strategic-Collaboration-with-Genentech-to-Research-Develop-and-Commercialize-Cancer-targeted-Allogeneic-T-cell-Therapies.html